ENTPD1 and myeloid sarcoma: Moreover, CD39+ Treg cells are thought to be involved in the beneficial effects of Teriflunomide in the EAE model (40) and an increase in CD39 expressing cells occurs in MS patients that receive Fingolimod (61).